Mosunetuzumab

FDA Drug Profile — Lunsumio, Lunsumio Velo

Mosunetuzumab is listed in the FDA National Drug Code directory with 8 NDC codes, marketed under brand names including Lunsumio, Lunsumio Velo. Available dosage forms: concentrate, injection, liquid.

Drug details

Generic Name
Mosunetuzumab
Brand Names
Lunsumio, Lunsumio Velo
Application Number
BLA761263
Sponsor
Genentech, Inc.
NDC Codes
8
Dosage Forms
CONCENTRATE, INJECTION, LIQUID
Routes
INTRAVENOUS, SUBCUTANEOUS
Active Ingredients
MOSUNETUZUMAB

Indications and Usage

1 INDICATIONS AND USAGE LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) 1.1 Follicular Lymphoma LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.